NCT07741877Not yet recruitingPhase 2
A Phase 2, Multicenter, Open-label Study of Lifileucel (Tumor-infiltrating Lymphocytes [TIL]) in Participants With Previously Treated Advanced Soft Tissue Sarcoma
Conditions
Trial Snapshot
- Phase
- Phase 2
- Status
- Not yet recruiting
- Enrollment
- 80
- Primary Endpoint
- Objective Response Rate
Study Overview
Brief Summary
A study of lifileucel (tumor-infiltrating lymphocytes) in adults with advanced soft tissue sarcoma ('SARATOGA')
Detailed Description
The purpose of this study is to investigate the efficacy and safety of the lifileucel regimen in participants with previously treated soft tissue sarcoma. The length of the study for each participant may be up to 5 calendar years after receiving lifileucel. After Screening, each participant will have surgery to remove some tumor pieces that will be used to make the lifileucel, followed by a baseline visit prior to study treatment. Participants will then receive the lifileucel treatment regimen. This includes 2 drugs (cyclophosphamide and fludarabine) for up to 5 days to decrease lymphocytes in the body, the lifileucel infusion (1 day), and up to 4 days of aldesleukin to boost the activity of the lifileucel. Study visits will be every 6 weeks for 6 months, then every 3 months until 5 calendar years after the lifileucel infusion.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 16 Years to 70 Years (Child, Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Participant must be ≥ 16 years of age at the time of signing the informed consent and assent.
- •Participants who are > 70 years of age may be allowed to enroll after the investigator discusses with the medical monitor.
- •Participant must have a confirmed diagnosis of histologically confirmed unresectable or metastatic UPS (Cohort 1) or DDLPS (Cohort 2), with or without a well-differentiated component, who have received ≥ 1 and a maximum of 3 prior systemic therapies, including ≥ 1 anthracycline-based regimen.
- •Participant has demonstrated progressive disease on or after the last line of therapy.
- •Participant is assessed as having at least one resectable lesion (or aggregate lesions) with an estimated minimum diameter of 1.5 cm (short axis) for lifileucel generation.
- •Following tumor resection for lifileucel generation, the participant will have at least one measurable lesion, as defined by RECIST v1.1 at Baseline.
- •Participant is expected to achieve washout from investigational or anticancer therapy(ies).
- •If the participant has preplanned surgical procedure(s), the procedure will take place at least 14 days (for major operative procedures) prior to the tumor resection. Wound healing will have occurred, and all complications will have resolved at the time of tumor resection.
- •Participant has recovered from all prior anticancer treatment-related AEs to Grade ≤ 1(per NCI-CTCAE), except for peripheral neuropathy, alopecia, or vitiligo.
- •Participants of childbearing potential or those with partners of childbearing potential must be willing to practice an approved method of highly effective birth control.
- •Participants must have adequate organ function.
- •Participant is willing to receive optimal supportive care, including intensive care, from enrollment until the first post-treatment tumor assessment.
Exclusion Criteria
- •Participant has symptomatic untreated brain metastases.
- •The participant has an ECOG performance status of ≥ 2, a need for urgent therapy due to rapidly progressive disease or tumor mass effect, or an estimated life expectancy of< 6 months.
- •Participant has an active medical illness(es) that, in the opinion of the investigator, would pose increased risks for study participation.
- •Participant has any form of primary immunodeficiency (eg, severe combined immunodeficiency disease [SCID] or AIDS).
- •Participant has a history of hypersensitivity to any component of the study intervention.
- •Participant had another primary malignancy within the previous 3 years (except for those that do not require treatment or have been curatively treated > 1 year ago, and in the judgment of the investigator does not pose a significant risk of recurrence.
- •Other protocol defined inclusion/exclusion criteria could apply.
Outcomes
Primary Outcomes
Objective Response Rate
Time Frame: 5 years
To evaluate the efficacy of lifileucel as measured by ORR per RECIST v1.1 as assessed by the IRC
Secondary Outcomes
- Complete Response Rate(5 years)
- Duration of Response(5 years)
- Disease Control Rate(5 years)
- Progression-Free Survival(5 years)
- Objective Response Rate(5 years)
- Overall Survival(5 years)
- Adverse Events(5 years)
Investigators
Similar Trials
Active, not recruiting
Phase 2
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced MelanomaNCT07288203Iovance Biotherapeutics, Inc.100
Recruiting
Phase 2
A study of lifileucel (tumor-infiltrating lymphocytes) in adults with advanced melanoma2025-522054-40-00Iovance Biotherapeutics Inc.69
Not yet recruiting
Phase 1
TILs Plus Third-Generation EGFR-TKI Therapy for TKI-Resistant NSCLCEGFR-TKI-resistant Non-Small Cell Lung CancerNCT07498595Tianjin Medical University General Hospital50
Not yet recruiting
Phase 2
Lisaftoclax Plus Pirtobrutinib in Relapsed or Refractory Mantle Cell Lymphoma After BTK-Targeted TherapyMantle Cell Lymphoma (MCL)NCT07684950Henan Cancer Hospital45
Recruiting
Phase 2
TIL Therapy in cSCC and MCCSkin CancerMerkel Cell CarcinomaNCT07288073Karam Khaddour, MD, MS14